After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...